Free Trial

Morphic Q2 2023 Earnings Report

Morphic Earnings Headlines

Morphic Ethical Equities Fund Limited
Eli Lilly acquires Morphic in IBD portfolio expansion
70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
MORF Jan 2025 25.000 put (MORF250117P00025000)
See More Morphic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Morphic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Morphic and other key companies, straight to your email.

About Morphic

Morphic (NASDAQ:MORF), a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

View Morphic Profile

More Earnings Resources from MarketBeat